Analyst Price Targets — IMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 10:50 am | — | Piper Sandler | $12.00 | $5.62 | TheFly | Immuneering price target lowered to $12 from $13 at Piper Sandler |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $12.00 | $6.49 | TheFly | Immuneering price target raised to $12 from $10 at Mizuho |
| September 25, 2025 12:57 pm | Jay Olson | Oppenheimer | $30.00 | $9.23 | TheFly | Immuneering price target raised to $30 from $21 at Oppenheimer |
| April 2, 2024 6:36 am | Graig Suvannavejh | Mizuho Securities | $8.00 | $2.75 | StreetInsider | Immuneering Corporation (IMRX) PT Lowered to $8 at Mizuho, 'maintain our favorable view on IMRX's innovative approach' |
| March 15, 2024 6:26 am | Michael Yee | Jefferies | $3.00 | $1.91 | StreetInsider | Jefferies Downgrades Immuneering Corporation (IMRX) to Hold |
| September 30, 2022 12:16 pm | Swapnil Malekar | Piper Sandler | $41.00 | $15.50 | TheFly | Immuneering transitions to clinical stage with IND approval, says Piper Sandler |
| July 9, 2022 6:13 am | Geulah Livshits | Loop Capital Markets | $18.00 | $7.28 | Pulse 2.0 | Immuneering (IMRX) Stock: Why It Surged 28.85% |
Latest News for IMRX
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the genetic alterations most commonly associated with resistance to RAS inhibitors, providing molecular rationale to treat with atebimetinib early NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Immuneering…
Immuneering (NASDAQ: IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as "extraordinary" early survival results for the company's lead program, atebimetinib, in first-line pancreatic cancer, and outlined multiple upcoming clinical and regulatory milestones across pancreatic and lung cancer. Phase II pancreatic cancer survival update
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast…
Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMRX.
U.S. House Trading
No House trades found for IMRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.